icon-folder.gif   Conference Reports for NATAP  
 
  63rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 9-12 2012
Back grey_arrow_rt.gif
 
 
 
ALS-2200, A Novel Once-daily Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity Over 7 Days in Treatmentnaïve Genotype 1 (GT1) Patients
 
 
  Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
 
1Marcellin, P., 2Popa, S., 2Berliba, A., 2 Moscalu, I., 1Boyer, N., 3Kauffman, R.S., 3 Koziel, M., 3Garg, V., 4Tong, M.J., 5Chanda S.M., 5 Zhang, Q., 5Westland, C., 5Beigelman, L., 5Blatt, L.M., and 5Fry, J. 1. Hopital Beaujon, Clichy, France
2. Republican Clinical Hospital, Chisinau, Moldova
3. Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA
4. Liver Center, Huntington Medical Research Institutes, Pasadena, CA, USA
5. Alios BioPharma, South San Francisco, CA, USA

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif